SRPT
NASDAQ · Biotechnology
Sarepta Therapeutics Inc
$17.57
-1.42 (-7.48%)
Open$18.91
Previous Close$18.99
Day High$18.92
Day Low$17.44
52W High$24.68
52W Low$14.68
Volume—
Avg Volume1.46M
Market Cap1.86B
P/E Ratio—
EPS$-1.82
SectorBiotechnology
Analyst Ratings
Hold
32 analysts
Price Target
+126.5% upside
Current
$17.57
$17.57
Target
$39.80
$39.80
$34.71
$39.80 avg
$61.57
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.32B | 1.74B | 549.72M |
| Net Income | -752,645,314 | -509,040,942 | -107,586,925 |
| Profit Margin | -32.5% | -30.8% | -19.6% |
| EBITDA | -717,714,459 | -512,383,509 | -125,300,242 |
| Free Cash Flow | — | — | -79,607,758 |
| Rev Growth | +33.1% | +33.1% | +15.5% |
| Debt/Equity | 0.73 | 0.73 | 0.72 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |